- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2015–2021 · research · R01
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Stress response networks in HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Identifying the roles of DNA rewinding enzymes on maintaining genome stability
Brendan D Price · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K01
Improving surgical decision-making in young women with breast cancer
Shoshana M Rosenberg · Dana-Farber Cancer Institute · funded by Agency for Healthcare Research and Quality
2015–2022 · research · R35
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
Shuji Ogino · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U01
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors
Joe W. Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · cooperative agreement · U54
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
Eric C. Holland · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U01
Genetics of Prostate Cancer in Africa
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2029 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
Nathanael Schiander Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Determining the mutational landscape of circulating multiple myeloma cells
Jens G Lohr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R37
Biochemical Mechanism of HIV DNA Integration
Alan N. Engelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2028 · research · R35
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U54
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
Eric C. Holland · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · cooperative agreement · U01
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors
Joe W. Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U24
Quantitative Radiomics System Decoding the Tumor Phenotype
Hugo Aerts · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U01
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors
Joe W. Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Elucidating and overcoming endocrine resistance driven by ESR1 mutations
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R37
Biochemical Mechanism of HIV DNA Integration
Alan N. Engelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R37
Biochemical Mechanism of HIV DNA Integration
Alan N. Engelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Testing the role of BATF as a pioneer transcription factor in effector T cells
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K01
Improving surgical decision-making in young women with breast cancer
Shoshana M Rosenberg · Dana-Farber Cancer Institute · funded by Agency for Healthcare Research and Quality
2015–2020 · research · R01
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors
Nathanael Schiander Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K01
Improving surgical decision-making in young women with breast cancer
Shoshana M Rosenberg · Dana-Farber Cancer Institute · funded by Agency for Healthcare Research and Quality
2015–2020 · research · R01
The function of cyclin C in tumorigenesis
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
